This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RXII RXi Pharmaceuticals (RXII) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About RXi Pharmaceuticals Stock (NASDAQ:RXII) Get RXi Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.25▼$1.3050-Day Range$0.36▼$0.5052-Week Range$0.31▼$7.70Volume139,747 shsAverage Volume1.73 million shsMarket Capitalization$5.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA. Read More Receive RXII Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RXi Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RXII Stock News HeadlinesRex International Holding Ltd (RXI.SG)October 26, 2023 | finance.yahoo.comGalena's Breast Cancer Vaccine Doomed to FailApril 19, 2023 | thestreet.comThere’s a new type of capitalismThe U.S. government has taken direct equity positions in at least 10 companies - Intel, U.S. Steel, Westinghouse, MP Materials, Lithium Americas, and others - plus roughly $2 billion in quantum computing investments. When these deals were announced, the stocks soared overnight. Porter Stansberry, founder of one of the world's largest financial research firms, says this shift away from free-market capitalism is the most consequential economic story in centuries - and almost no one is prepared for it. He's identified the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this new reality.June 20 at 1:00 AM | Porter & Company (Ad)Q4 2022 Catalyst Pharmaceuticals Inc Earnings CallMarch 20, 2023 | finance.yahoo.comiShares Global Consumer Discretionary ETF (RXI)September 30, 2022 | finance.yahoo.comSee More Headlines RXII Stock Analysis - Frequently Asked Questions How were RXi Pharmaceuticals' earnings last quarter? RXi Pharmaceuticals Co. (NASDAQ:RXII) posted its earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.02 million. RXi Pharmaceuticals had a negative net margin of 4,990.20% and a negative trailing twelve-month return on equity of 412.15%. When did RXi Pharmaceuticals' stock split? Shares of RXi Pharmaceuticals reverse split on the morning of Monday, January 8th 2018.The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of RXi Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that RXi Pharmaceuticals investors own include Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Protalix BioTherapeutics (PLX) and Anavex Life Sciences (AVXL). Company Calendar Last Earnings8/14/2018Today6/20/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RXII CIK1533040 Webwww.rxipharma.com Phone(508) 767-3861FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($4.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.45 million Net Margins-4,990.20% Pretax MarginN/A Return on Equity-412.15% Return on Assets-179.54% Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.77 Sales & Book Value Annual Sales$10 thousand Price / Sales569.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book1.69Miscellaneous Outstanding Shares4,380,000Free FloatN/AMarket Cap$5.69 million OptionableNot Optionable Beta2.07 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:RXII) was last updated on 6/20/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share RXi Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
